| Autor: |
James, Larkin, Michael P, Brown, Ana M, Arance, Axel, Hauschild, Paola, Queirolo, Michele Del, Vecchio, Paolo A, Ascierto, Ivana, Krajsová, Jacob, Schachter, Bart, Neyns, Claus, Garbe, Vanna Chiarion, Sileni, Mario, Mandalà, Helen, Gogas, Enrique, Espinosa, Geke, Hospers, Paul, Lorigan, Marta, Nyakas, Alex, Guminski, Gabriela, Liszkay, Piotr, Rutkowski, Wilson, Miller, Margarita, Donica, Martina, Makrutzki, Christian, Blank |
| Rok vydání: |
2018 |
| Předmět: |
|
| Zdroj: |
European journal of cancer (Oxford, England : 1990). 107 |
| ISSN: |
1879-0852 |
| Popis: |
The oncogenic BRAF inhibitor vemurafenib improves outcomes for patients with advanced BRAFIn this open-label, multicentre study, patients with previously treated or untreated melanoma and the BRAFBetween March 2011 and January 2013, 3224 patients were enrolled, and 3219 patients received ≥1 dose of vemurafenib (safety population); median follow-up time was 33.4 months. Vemurafenib's long-term benefits were confirmed, and no new safety signals identified. The prognostic index showed between-group differences in OS, with tight, non-overlapping confidence intervals. Validation in a pooled group of 666 vemurafenib-treated clinical trial patients revealed a similar pattern; the pattern was similar in 280 patients treated with vemurafenib plus cobimetinib.Final results from the vemurafenib safety study confirm vemurafenib's tolerability in BRAF |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect